



Published in final edited form as:

Crit Care Med. 2016 September ; 44(9): 1744–1753. doi:10.1097/CCM.0000000000001811.

Depressive symptoms after critical illness: a systematic review and meta-analysis

Anahita Rabiee, MD^{1,2}, Sina Nikayin, MD^{1,2}, Mohamed D. Hashem, MD^{1,2}, Minxuan Huang, ScM^{1,2}, Victor D. Dinglas, MPH^{1,2}, O. Joseph Bienvenu, MD, PhD^{1,3}, Alison E. Turnbull, DVM, MPH, PhD^{1,2,4}, Dale M. Needham, FCPA, MD, PhD^{1,2,5}

¹Outcomes After Critical Illness and Surgery Group, Johns Hopkins University, Baltimore, MD

²Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD

³Department of Psychiatry and Behavior Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD

⁴Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

⁵Department of Physical Medicine and Rehabilitation, School of Medicine, Johns Hopkins University, Baltimore

Abstract

Objective: To synthesize data on prevalence, natural history, risk factors and post-intensive care unit (ICU) interventions for depressive symptoms in ICU survivors

Data Sources: PubMed, EMBASE, CINAHL, PsycINFO, CENTRAL (1970 – 2015)

Study Selection: Studies measuring depression after hospital discharge using a validated instrument in >20 adults from non-specialty ICUs

Data Extraction: Duplicate independent review and data abstraction

Data Synthesis: The search identified 27,334 titles, with 42 eligible articles on 38 unique studies (n=4,113). The Hospital Anxiety and Depression Scale-Depression subscale (HADS-D), was used most commonly (58%). The pooled HADS-D prevalence (95% confidence interval (CI)) of depressive symptoms at a threshold score ≥ 8 was 29% (22–36%) at 2–3 months (12 studies, n=1,078), 34% (24–43%) at 6 months, (7 studies, n=760), and 29% (23–34%) at 12–14 months, (6 studies, n=1,041). The prevalence of supra-threshold depressive symptoms (compatible with HADS-D ≥ 8) across all studies, using all instruments, was between 29–30% at all 3 time points. The pooled change in prevalence (95% CI) from 2–3 to 6 months (4 studies, n=387) was 5% (–1% to +12%), and from 6 to 12 months (3 studies, n=412) was 1% (–6% to +7%). Risk factors included pre-ICU psychological morbidity and presence of in-ICU psychological distress

symptoms. We did not identify any post-ICU intervention with strong evidence of improvement in depressive symptoms.

Conclusions: Clinically important depressive symptoms occurred in approximately one-third of ICU survivors, and were persistent through 12-month follow-up. Greater research into treatment is needed for this common and persistent post-ICU morbidity.

Keywords

Depression; critical illness; critical care; meta-analysis; review

INTRODUCTION

Increasing numbers of patients are surviving critical illness (1,2). These survivors often experience long-term physical, cognitive and mental health impairments (3–7). Within the mental health sequelae of critical illness, depressive symptoms are an important issue. Depressive symptoms can negatively impact survivors' quality of life (6,8). Moreover, such symptoms can prevent survivors from returning to work, participating in social roles, and coping with physical limitations during recovery (6).

Recognition of depressive symptoms in intensive care unit (ICU) survivors is growing, with the number of studies published on this topic nearly doubling in the last 5 years. Therefore, our objectives were to synthesize existing data to: 1) estimate the prevalence of depressive symptoms after critical illness, 2) describe longitudinal changes in depressive symptoms after critical illness, 3) identify risk factors associated with depressive symptoms, and 4) identify post-ICU interventions that prevent or treat depressive symptoms.

MATERIALS AND METHODS

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (9) to report our systematic review and meta-analysis. No publicly accessible protocol was registered for this systematic review.

Search Strategy

We searched five electronic databases (PubMed, EMBASE, Cumulative Index of Nursing and Allied Health Literature (CINAHL), PsycINFO®, and the Cochrane Controlled Trials Registry (CENTRAL)) from 1970 through March 13, 2015, to identify eligible studies. Because articles may have included evaluation of depressive symptoms in combination with other outcomes, our search strategy focused on articles with any outcome assessments after hospital discharge in survivors of critical illness, using a combination of keywords and controlled vocabulary for the concepts of “intensive care” combined with “outcome assessment” and “follow-up” (Supplemental Table 1). The search strategy was not limited by language of publication. We also performed a manual search of reference lists from relevant review articles and all articles eligible for this systematic review.

Study Selection

We used the following inclusion criteria: 1) study population consisted of adult (>16 years old) survivors of critical illness, and 2) depressive symptoms assessed using a validated measure after hospital discharge. We excluded studies meeting any of the following criteria: 1) <50% ICU patients in study population, 2) primary focus on patients from a specialty ICU (e.g., trauma or neurological ICU) or with a specific disease (e.g., cardiac disease, acute respiratory distress syndrome (ARDS)), 3) <20 patients at follow-up, or 4) primary focus on evaluating psychometric properties of a questionnaire. We excluded abstracts and dissertations not published in a peer-reviewed journal.

Trained reviewers screened titles/abstracts and then full-text articles, in duplicate, using DistillerSR© (2014 Evidence Partners, Ottawa, Canada). Disagreement regarding eligibility was resolved by consensus.

Data Abstraction

Data were abstracted by two independent reviewers from each eligible article, with any conflicts resolved by consensus in consultation with an independent co-author (DMN) or (AET). We collected the following data from each eligible article: study design, patient population, baseline patient characteristics, proportion of patients with pre-existing psychiatric illness, timing and sample size at each depression assessment, depressive symptom assessment instrument and scoring method, point prevalence of depressive symptoms (indicated by having a score above a predefined threshold), potential risk factors for depressive symptoms, and any post-ICU interventions to prevent or treat depressive symptoms. We contacted authors for additional data when necessary. When risk factors were assessed in >1 study, we categorized them as pre-ICU, ICU, or post-ICU. We used analyses from the first follow-up assessment after hospital discharge for studies with longitudinal evaluations of risk factors and recorded risk factor associations from multivariable regressions, when available.

Risk of Bias Assessment

We conducted risk of bias assessment using the Cochrane Risk of Bias methodology (10) for randomized controlled trials (RCTs) and an adaptation of Newcastle Ottawa Scale (11) for observational studies (Supplemental Table 2).

Statistical Analysis

First, the pooled prevalence of depressive symptoms was estimated by pooling data from all studies that assessed depressive symptoms using the most common measurement instrument in this systematic review (i.e., the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D)). These data were used to estimate: 1) mean (standard deviation, SD) HADS-D score, and 2) point prevalence of depressive symptoms, defined as a HADS-D score ≥ 8 and ≥ 11 . Both thresholds have been recommended for the HADS-D (12), with the optimal balance between sensitivity and specificity occurring at ≥ 8 (13). Data were pooled for the 3 most commonly reported follow-up time points in eligible studies: 2–3 months, 6 months and 12–14 months.

Second, we combined studies using different instruments for depressive symptoms to create a pooled prevalence, using similar thresholds across instruments as previously described (14).

Third, in studies assessing depressive symptoms in the exact same patient cohort at two different time points, we also calculated the change in mean HADS-D scores and depressive symptom prevalence between 2–3 to 6 months and 6 to 12 months.

Pooled mean HADS-D scores and depressive symptom prevalences were estimated using linear and binominal random effects models, respectively, with a random intercept for the study. The I^2 statistic was used to evaluate between-study statistical heterogeneity, with a value $>50\%$ interpreted as substantial heterogeneity (15). Two separate sensitivity analyses were conducted. First, we removed patient groups undergoing post-ICU interventions to limit the potential effects that any intervention may have had on depressive symptoms prevalence. Second, we removed studies with high risk of bias based on either not reporting or having known high loss to follow-up. We did not assess publication bias due to an insufficient number of studies (16). STATA 13.1 (Stata Corporation, College Station, TX) was used to conduct all analyses.

RESULTS

Description of Search and Study Characteristics

We identified 27,334 citations and reviewed 18,693 unique titles and abstracts (after removing duplicates across databases), and 1,579 full text articles, with 42 publications on 38 unique studies meeting eligibility criteria (Supplemental Fig. 1). The 38 unique studies, included 9 RCTs (17–25), 24 cohort studies (26–49), 4 cross-sectional studies (50–53) and 1 case-series (54) (Supplemental Table 3). A total of 4,113 patients were included in the eligible studies, with most assessments occurring between 1 and 12 months after discharge (Table 1). A total of 18 (47%) of 38 studies included assessments of depressive symptoms at >1 time point after discharge. Fourteen studies (37%; $n=1,188$) were conducted in the United Kingdom, (17–20,24,28,29,33,36,37,40,44,50,53) and 10 (26%, $n=1,162$) were conducted in the United States (22,26,27,30,32,34,45,47–49).

Only 6 studies collected data on the use of antidepressants, with only 1 study collecting data both before and after ICU admission. This study showed that 24% of patients were taking antidepressant in the week before ICU treatment and 49% received an antidepressant medication within the first 2 months after critical illness (34). The same study revealed that suicidal ideation was endorsed by 23% of depressed patients after critical illness. No other study assessed for suicidal ideation. No study assessed the association between use of antidepressant in the ICU and depression at follow-up.

Risk of Bias Assessment

Among the 9 RCTs, randomization and allocation concealment were adequate in most studies (Supplemental Table 4). Double-blinding was feasible in 1 RCT (17). Among the observational studies, 13 (45%) had adequate follow-up (Supplemental Table 2).

Measures and Prevalence of depressive symptom

The most common measurement instrument was the HADS-D in 22 (58%) studies, followed by the Center for Epidemiological Studies Depression scale (CES-D) in 6 (16%) and Beck Depression Inventory (BDI-II) in 4 (11%) studies (Table 1). Assessments were conducted in-person, by mail, and by phone in 15 (39%), 12 (32%), and 10 (26%) of the 38 studies, respectively, with some using >1 method and 7 (18%) studies not clearly reporting the method. Patients with prior psychiatric history were excluded in 4 studies, with 15 studies reporting the prevalence of prior psychiatric problems before hospital admission (range: 10% to 54% between studies) (Table 1).

The prevalence of depressive symptoms across all included studies, using 7 distinct instruments with different cut-offs, ranged from 4% to 64%. The pooled mean (95% confidence interval (CI)) HADS-D score was 5.5 (4.8–6.1; $I^2 = 82\%$) at 2–3 months, 5.6 (5.1–6.1; $I^2 = 66\%$) at 6 months, and 5.2 (4.5–5.8; $I^2 = 81\%$) at 12–14 months. For studies using the HADS-D instrument, the pooled depressive symptoms prevalence (95% CI) at the 8 threshold was 29% (22–36%; $I^2 = 84\%$), 34% (24–43%; $I^2 = 88\%$), and 29% (23–34%; $I^2 = 76\%$), respectively. Across studies using any instrument, the prevalence of supra-threshold depressive symptoms (compatible with HADS-D 8) was between 29–30% at all 3 time points. At the 11 threshold, the pooled prevalence (95% CI) was 17% (12–21%; $I^2 = 77\%$) at 2–3 months, 17% (10–23%; $I^2 = 83\%$) at 6 months, and 13% (10–16%; $I^2 = 52\%$) at 12–14 months (Table 2). Sensitivity analyses did not materially change these results or decrease heterogeneity.

In 387 patients (4 studies) (17,18,25,40), with HADS-D data on identical patient cohorts at 2 or 3 months and 6 months, the pooled difference in mean score (95% CI), comparing the latter time point to the early time point, was 0.1 (–0.2 to 0.3; $I^2 = 42\%$), and the pooled difference (95% CI) in depressive symptom prevalence at 8 and 11 thresholds was 5% (–1% to +12%; $I^2 = 0\%$) and –1% (–8% to +5%; $I^2 = 38\%$), respectively. In 412 patients (3 studies) (18,25,33), with HADS-D data at both 6 and 12 months, the pooled mean difference in HADS-D score was 0 (–0.2 to +0.1; $I^2 = 0\%$), and the pooled difference in depressive symptoms prevalence was 1% (–6% to +7%; $I^2 = 0\%$) and 1% (–4% to +6%; $I^2 = 0\%$) for 8 and 11 respectively.

Risk factors associated with depressive symptoms

Among studies that estimated the association between age, sex, and depressive symptoms, age was not associated with depressive symptoms in 9 of 11 (26,33,34,36,44,45,47,53,55) and sex was not associated in 8 of 8 (28,34,44,45,51–53,55) studies (Table 3). Pre-ICU psychological morbidities were strongly associated with depressive symptoms in 4 of 5 studies (34,44,45,52). Severity of illness and ICU or hospital length of stay were not associated with depressive symptoms in 6 of 6 (29,33,36,45,51,53) and 5 of 5 (33,36,44,50,53) studies, respectively. Benzodiazepine use and duration of sedation were not associated with depressive symptoms in 3 of 3 studies (29,44,45). Sedation minimization strategies, such as daily sedation interruption (22,49), light sedation (21), and a no sedation protocol (23) were not associated with depressive symptoms in 4 of 4 studies

The presence of psychological distress symptoms in the ICU or hospital had a significant association with depressive symptoms at follow-up, with such symptoms evaluated in a variety of ways, including ICU mood symptoms (anger, nervousness) (44), acute stress symptoms (45), stressful experiences of ICU stay (35), and depressive symptoms in the hospital (33). “Delusional memories” and lack of factual memories were associated with more depressive symptoms at follow-up in 2 of 2 (29,55) and 3 of 5 (29,33,44) studies, respectively. The association between delirium and depressive symptoms were assessed in 3 studies. One showed a positive unadjusted association (44), the second showed a positive association at one year follow-up (not at 3 months),(56) and the third showed no association (45).

Depressive symptoms were concurrently correlated with greater anxiety and PTSD symptoms in 5 of 5 studies (19,36,50–52) and with worse quality of life in 2 of 2 studies (36,52).

Interventions to Reduce Depressive Symptoms

No study specifically assessed pharmacological intervention in this population. However, physical rehabilitation after ICU discharge was assessed in 3 studies, with significant benefit reported in 1 cohort study (37) and in 1 RCT when combined with oral supplementation with essential amino acids (24) (Table 4). In-hospital rehabilitation after ICU discharge did not show significant benefit in 1 RCT (25).

Use of an ICU diary was not associated with significant reduction in depressive symptoms in 1 pre-post cohort study. In 1 RCT (41), the group receiving an ICU diary combined with counseling demonstrated a significant decrease in depressive symptoms over time, but the difference between treatment groups was not statistically significant (19). A nurse-led ICU follow-up clinic did not have significant benefit in 1 RCT (18), while a multidisciplinary follow-up clinic showed benefit for women (but not men) in 1 RCT on a combined outcome of depression, anxiety and PTSD symptoms (43).

DISCUSSION

This systematic review and meta-analysis in non-specialty populations of ICU survivors demonstrates that clinically important depressive symptoms occur in approximately 30% of patients over the first 12 months after critical illness. Studies with longitudinal assessment of depressive symptoms in fixed cohorts of survivors showed no significant change in HADS-D scored or prevalence of depressive symptoms during the first 12 months after discharge.

The prevalence of depressive symptoms in this review is similar to the 31–45% prevalence of depressive symptoms in cardiac patients without critical illness (57), and markedly higher than studies in American and European general populations with a prevalence of 8–11%, (58–60). Pooled data evaluating the longitudinal prevalence of post-ICU depressive symptoms showed no significant change during the first 12 months post-ICU. The reason for this concerning finding is not clear, but is similar to that of cardiac patients (57).

The 38 unique studies in this systematic review used 7 different instruments, with variability in scoring, timing of follow-up, and risk factors evaluated, making synthesis and comparisons across studies challenging. The HADS-D was clearly the most common instrument, used in >50% of studies. Validation of an instrument to measure depressive symptoms in critical illness survivors after discharge, and consistent use of this instrument with standardized scoring methods, thresholds, and reporting would help advance the field (61). Given that it is the most commonly used instrument, the HADS would be a particularly relevant instrument for validation in a population of ICU survivors. Notably, the HADS subscales have been validated in general medical patients, and some preliminary validation has been done in subgroups of critical illness survivors (62,63).

Important patient factors consistently not associated with depressive symptoms included age and sex. This finding differs from studies in the general population in which depressive symptoms are twice as common in females (64), and more common in the 40–59 year age group (58). Future research is needed to help understand any unique attributes of patients with critical illness and relevant mechanisms that may contribute to this finding. Aspects unique to critical illness (e.g., neuro-inflammation) might be an etiological factor that affects both sexes similarly.

Many ICU factors, such as admission diagnosis, severity of illness, sedation and analgesia, and length of stay, also were consistently not associated with depressive symptoms at follow-up, similar to prior findings for other psychological symptoms in ICU survivors (7,65). Hence, screening efforts for post-ICU depressive symptoms among general ICU survivors should be quite broad, considering both sexes, all ages, and the full range of severity of illness and length of stay. Focusing only on patients with a high severity of illness or a long length of stay may overlook a large number of symptomatic ICU survivors. Rather, identifying patients with pre-existing psychological morbidity and psychological distress symptoms in the hospital may help maximize prevention and early intervention efforts. Moreover, given high comorbidity of depression with anxiety and PTSD symptoms after critical illness, as demonstrated in this systematic review, patients who screen positive for depression, should be evaluated for a full spectrum of psychological sequelae.

There were inconsistent results across 3 studies regarding the potential association of ICU delirium with post-discharge depressive symptoms. More research is required in this area.

There was no strong evidence to support a post-ICU intervention to prevent or treat depressive symptoms. Nevertheless, some studies suggested that post-ICU out-patient physical rehabilitation interventions reduced depressive symptoms, consistent with data in cardiac patients (66). Hence, the potential mental and physical benefits of rehabilitation and exercise interventions in general ICU survivors merit continued research. No study assessed the effect of pharmacological treatment options in this population as an intervention. Similar treatments in cardiac patients have shown to be effective (67). This is an important area for future research.

Among observational studies and randomized trials, there were high rates of loss to follow-up, suggesting potential selection bias (68,69). Since depressive symptoms may influence

patients' willingness to participate, loss to follow-up may bias results from both interventional and prevalence/risk factor studies (including the results of this systematic review) and potentially underestimate the prevalence of depressive symptoms.

There are potential limitations of this systematic review. First, with the exception of 2 studies (34,54), depressive symptoms were assessed using questionnaires, most of which have not been rigorously evaluated for their psychometric performance in ICU survivors. Ideally, studies would use a clinician-administered, semi-structured diagnostic interview. However, this approach is often not feasible due to the required expertise of the interviewer and the time required to complete the assessment, which may be particularly burdensome in studies with repeated longitudinal assessments and evaluation of other psychological and physical outcome measures of interest. Moreover, diagnostic semi-structured interviews do not provide a quantitative measure of symptom severity which is useful for research studies. Second, there was substantial statistical heterogeneity in this meta-analysis that did not improve with sensitivity analyses. Hence, caution is advised in interpreting the pooled results of depressive symptom means and prevalences. Third, the existing data do not clarify whether depressive symptoms are the result of critical illness, or if post-ICU depressive symptoms mainly reflect pre-admission morbidity or are a result of hospitalization without any unique contribution of an ICU stay. Finally, although we attempted to identify all potentially relevant studies, it is possible that eligible studies were inadvertently omitted from this systematic review.

CONCLUSION

Depressive symptoms occurred in approximately 30% of general critical illness survivors with persistent severity over 12 month longitudinal follow-up. ICU survivors with comorbid psychopathology before and during their hospitalization have a higher prevalence of depressive symptoms after discharge. However, age, sex, severity of illness and length of stay were consistently not associated with depressive symptoms; hence, a large pool of ICU survivors are at-risk for depressive symptoms. No post-ICU intervention for preventing or treating depressive symptoms was supported by strong evidence, although physical rehabilitation after discharge merits further investigation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank the following investigators who provided additional data from their research studies to permit this meta-analysis: Drs. Ceri Battle, Brian Cuthbertson, Maité Garrouste-Orgeas, Richard Griffiths, Christina Jones, David McWilliams, Hilde Myhren, Giles Peek, Janice Rattray, Anna Schandl, Kannika Sukantarat, Marike van der Schaaf, and Timothy Walsh. We also thank the following people for their assistance in literature searches, screening titles and abstracts, data collection and management: Dr. Deepti Baheti, Mr. Wesley Davis, Dr. Mohamed Farhan Nasser, Dr. Ann Parker, Ms. Carrie Price and Mr. Ayush Singh.

Funding Support:

This research was supported by the National Heart, Lung, and Blood Institute [R24HL111895].

References:

1. Zimmerman JE, Kramer AA, Knaus WA. Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012. *Crit Care Lond Engl*. 2013;17(2):R81.
2. Needham DM, Bronskill SE, Calinawan JR, Sibbald WJ, Pronovost PJ, Laupacis A. Projected incidence of mechanical ventilation in Ontario to 2026: Preparing for the aging baby boomers. *Crit Care Med*. 2005 3;33(3):574–9. [PubMed: 15753749]
3. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional Disability 5 Years after Acute Respiratory Distress Syndrome. *N Engl J Med*. 2011 4 7;364(14):1293–304. [PubMed: 21470008]
4. Fan E, Dowdy DW, Colantuoni E, Mendez-Tellez PA, Sevransky JE, Shanholtz C, et al. Physical Complications in Acute Lung Injury Survivors: A Two-Year Longitudinal Prospective Study. *Crit Care Med*. 2014 4;42(4):849–59. [PubMed: 24247473]
5. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, et al. Long-Term Cognitive Impairment after Critical Illness. *N Engl J Med*. 2013 10 3;369(14):1306–16. [PubMed: 24088092]
6. Davydow DS, Gifford JM, Desai SV, Bienvenu OJ, Needham DM. Depression in general intensive care unit survivors: a systematic review. *Intensive Care Med*. 2009 5;35(5):796–809. [PubMed: 19165464]
7. Parker AM, Sricharoenchai T, Raparla S, Schneck KW, Bienvenu OJ, Needham DM. Posttraumatic Stress Disorder in Critical Illness Survivors: A Metaanalysis*. *Crit Care Med*. 2015 5;43(5):1121–9. [PubMed: 25654178]
8. Davydow DS, Desai SV, Needham DM, Bienvenu OJ. Psychiatric Morbidity in Survivors of the Acute Respiratory Distress Syndrome: A Systematic Review: *Psychosom Med*. 2008 5;70(4):512–9. [PubMed: 18434495]
9. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*. 2009 7 21;6(7):e1000097. [PubMed: 19621072]
10. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011 10 18;343(oct18 2):d5928–d5928. [PubMed: 22008217]
11. Wells G, Shea B, O'connell D. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Metaanalyses. 2000 [Internet]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
12. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983 6;67(6):361–70. [PubMed: 6880820]
13. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002 2;52(2):69–77. [PubMed: 11832252]
14. Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire. *Arthritis Care Res*. 2011 11;63(S11):S454–66.
15. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002 6 15;21(11):1539–58. [PubMed: 12111919]
16. Sedgwick P Meta-analysis: testing for reporting bias. *BMJ*. 2015 1 2;350(jan02 1):g7857–g7857. [PubMed: 25555827]
17. Jones C, Skirrow P, Griffiths RD, Humphris GH, Ingleby S, Eddleston J, et al. Rehabilitation after critical illness: A randomized, controlled trial: *Crit Care Med*. 2003 10;31(10):2456–61. [PubMed: 14530751]
18. Cuthbertson BH, Rattray J, Campbell MK, Gager M, Roughton S, Smith A, et al. The PRaCTICaL study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness: a pragmatic randomised controlled trial. *BMJ*. 2009 10 16;339(oct16 1):b3723–b3723. [PubMed: 19837741]

19. Knowles RE, TARRIER N. Evaluation of the effect of prospective patient diaries on emotional well-being in intensive care unit survivors: A randomized controlled trial*. *Crit Care Med.* 2009 1;37(1):184–91. [PubMed: 19050634]
20. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *The Lancet.* 2009 10;374(9698):1351–63.
21. Treggiari MM, Romand J-A, Yanez ND, Deem SA, Goldberg J, Hudson L, et al. Randomized trial of light versus deep sedation on mental health after critical illness*. *Crit Care Med.* 2009 9;37(9):2527–34. [PubMed: 19602975]
22. Jackson JC, Girard TD, Gordon SM, Thompson JL, Shintani AK, Thomason JWW, et al. Long-term Cognitive and Psychological Outcomes in the Awakening and Breathing Controlled Trial. *Am J Respir Crit Care Med.* 2010 7 15;182(2):183–91. [PubMed: 20299535]
23. Strøm T, Stylsvig M, Toft P. Long-term psychological effects of a no-sedation protocol in critically ill patients. *Crit Care.* 2011;15(6):R293. [PubMed: 22166673]
24. Jones C, Eddleston J, McCairn A, Dowling S, McWilliams D, Coughlan E, et al. Improving rehabilitation after critical illness through outpatient physiotherapy classes and essential amino acid supplement: A randomized controlled trial. *J Crit Care* [Internet]. 2015 5 [cited 2015 Jul 14]; Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0883944115002646>
25. Walsh TS, Salisbury LG, Merriweather JL, Boyd JA, Griffith DM, Huby G, et al. Increased Hospital-Based Physical Rehabilitation and Information Provision After Intensive Care Unit Discharge: The RECOVER Randomized Clinical Trial. *JAMA Intern Med.* 2015 6 1;175(6):901. [PubMed: 25867659]
26. Chelluri L, Pinsky MR, Donahoe MP, Grenvik A. Long-term outcome of critically ill elderly patients requiring intensive care. *JAMA.* 1993 6 23;269(24):3119–23. [PubMed: 8505814]
27. Broslawski GE, Elkins M, Albus M. Functional abilities of elderly survivors of intensive care. *J Am Osteopath Assoc.* 1995 12;95(12):712–7. [PubMed: 8557555]
28. Eddleston JM, White P, Guthrie E. Survival, morbidity, and quality of life after discharge from intensive care. *Crit Care Med.* 2000 7;28(7):2293–9. [PubMed: 10921555]
29. Jones C, Griffiths RD, Humphris G, Skirrow PM. Memory, delusions, and the development of acute posttraumatic stress disorder-related symptoms after intensive care. *Crit Care Med.* 2001 3;29(3):573–80. [PubMed: 11373423]
30. Jackson JC, Hart RP, Gordon SM, Shintani A, Truman B, May L, et al. Six-month neuropsychological outcome of medical intensive care unit patients: *Crit Care Med.* 2003 4;31(4):1226–34. [PubMed: 12682497]
31. Boyle M, Murgu M, Adamson H, Gill J, Elliott D, Crawford M. The effect of chronic pain on health related quality of life amongst intensive care survivors. *Aust Crit Care.* 2004 8;17(3):104–13. [PubMed: 15493858]
32. Chelluri L, Im KA, Belle SH, Schulz R, Rotondi AJ, Donahoe MP, et al. Long-term mortality and quality of life after prolonged mechanical ventilation*: *Crit Care Med.* 2004 Jan;32(1):61–9.
33. Rattray JE, Johnston M, Wildsmith JAW. Predictors of emotional outcomes of intensive care. *Anaesthesia.* 2005 11;60(11):1085–92. [PubMed: 16229693]
34. Weinert C, Meller W. Epidemiology of depression and antidepressant therapy after acute respiratory failure. *Psychosomatics.* 2006 10;47(5):399–407. [PubMed: 16959928]
35. Samuelson KAM, Lundberg D, Fridlund B. Stressful memories and psychological distress in adult mechanically ventilated intensive care patients ? a 2-month follow-up study. *Acta Anaesthesiol Scand.* 2007 7;51(6):671–8. [PubMed: 17567267]
36. Sukantarat K, Greer S, Brett S, Williamson R. Physical and psychological sequelae of critical illness. *Br J Health Psychol.* 2007 2;12(1):65–74. [PubMed: 17288666]
37. McWilliams D, Atkinson D, Carter A, Foëx B, Benington S, Conway D. Feasibility and impact of a structured, exercise-based rehabilitation programme for intensive care survivors. *Physiother Theory Pract.* 2009 11;25(8):566–71. [PubMed: 19925264]

38. van der Schaaf M, Beelen A, Dongelmans D, Vroom M, Nollet F. Functional status after intensive care: A challenge for rehabilitation professionals to improve outcome. *J Rehabil Med*. 2009;41(5):360–6. [PubMed: 19363570]
39. Myhren H, Ekeberg Ø, Tøien K, Karlsson S, Stokland O. Posttraumatic stress, anxiety and depression symptoms in patients during the first year post intensive care unit discharge. *Crit Care*. 2010;14(1):R14. [PubMed: 20144193]
40. Rattray J, Crocker C, Jones M, Connaghan J. Patients' perceptions of and emotional outcome after intensive care: results from a multicentre study. *Nurs Crit Care*. 2010 4;15(2):86–93. [PubMed: 20236435]
41. Garrouste-Orgeas M, Coquet I, Périer A, Timsit J-F, Pochard F, Lancrin F, et al. Impact of an intensive care unit diary on psychological distress in patients and relatives*: *Crit Care Med*. 2012 7;40(7):2033–40. [PubMed: 22584757]
42. McKinley S, Aitken LM, Alison JA, King M, Leslie G, Burmeister E, et al. Sleep and other factors associated with mental health and psychological distress after intensive care for critical illness. *Intensive Care Med*. 2012 4;38(4):627–33. [PubMed: 22318635]
43. Schandl A, Bottai M, Hellgren E, Sundin Ö, Sackey P. Gender differences in psychological morbidity and treatment in intensive care survivors - a cohort study. *Crit Care*. 2012;16(3):R80. [PubMed: 22578016]
44. Wade DM, Howell DC, Weinman JA, Hardy RJ, Mythen MG, Brewin CR, et al. Investigating risk factors for psychological morbidity three months after intensive care: a prospective cohort study. *Crit Care*. 2012;16(5):R192. [PubMed: 23068129]
45. Davydow DS, Zatzick D, Hough CL, Katon WJ. A longitudinal investigation of posttraumatic stress and depressive symptoms over the course of the year following medical–surgical intensive care unit admission. *Gen Hosp Psychiatry*. 2013 5;35(3):226–32. [PubMed: 23369507]
46. Raveau T, Annweiler C, Chudeau N, Gergaud S, Thiery S, Gautier J, et al. Comprehensive geriatric assessment in intensive care unit: a pilot study (pre-Seniora). *Gériatrie Psychol Neuropsychiatr Viellissement*. 2013 12;(4):389–95.
47. Jackson JC, Pandharipande PP, Girard TD, Brummel NE, Thompson JL, Hughes CG, et al. Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study. *Lancet Respir Med*. 2014 5;2(5):369–79. [PubMed: 24815803]
48. Parsons EC, Hough CL, Vitiello MV, Zatzick D, Davydow DS. Insomnia is associated with quality of life impairment in medical-surgical intensive care unit survivors. *Heart Lung J Acute Crit Care*. 2015 3;44(2):89–94.
49. Kress JP, Gehlbach B, Lacy M, Pliskin N, Pohlman AS, Hall JB. The Long-term Psychological Effects of Daily Sedative Interruption on Critically Ill Patients. *Am J Respir Crit Care Med*. 2003 12 15;168(12):1457–61. [PubMed: 14525802]
50. Scragg P, Jones A, Fauvel N. Psychological problems following ICU treatment. *Anaesthesia*. 2001 1;56(1):9–14. [PubMed: 11167429]
51. Kowalczyk M, Nestorowicz A, Fijałkowska A, Kwiatosz-Muc M. Emotional sequelae among survivors of critical illness: a long-term retrospective study. *Eur J Anaesthesiol*. 2013 3;30(3):111–8. [PubMed: 23358098]
52. Paparrigopoulos T, Melissaki A, Tzavellas E, Karaiskos D, Ilias I, Kokras N. Increased comorbidity of depression and post-traumatic stress disorder symptoms and common risk factors in intensive care unit survivors: A two-year follow-up study. *Int J Psychiatry Clin Pract*. 2014 1;18(1):25–31. [PubMed: 24151923]
53. Battle C, James K, Temblett P. Depression following critical illness: Analysis of incidence and risk factors. *J Intensive Care Soc*. 2015 5 1;16(2):105–8. [PubMed: 28979391]
54. Risnes I, Heldal A, Wagner K, Boye B, Haraldsen I, Leganger S, et al. Psychiatric outcome after severe cardio-respiratory failure treated with extracorporeal membrane oxygenation: a case-series. *Psychosomatics*. 2013 10;54(5):418–27. [PubMed: 23756125]
55. Myhren H, Tøien K, Ekeberg Ø, Karlsson S, Sandvik L, Stokland O. Patients' memory and psychological distress after ICU stay compared with expectations of the relatives. *Intensive Care Med*. 2009 12;35(12):2078–86. [PubMed: 19756511]

56. Jackson JC, Pandharipande PP, Girard TD, Brummel NE, Thompson JL, Hughes CG, et al. Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study. *Lancet Respir Med*. 2014 5;2(5):369–79. [PubMed: 24815803]
57. Huffman JC, Celano CM, Beach SR, Motiwala SR, Januzzi JL. Depression and Cardiac Disease: Epidemiology, Mechanisms, and Diagnosis. *Cardiovasc Psychiatry Neurol*. 2013;2013:1–14.
58. Pratt LA, Brody DJ. Depression in the U.S. household population, 2009–2012. *NCHS Data Brief*. 2014 12;(172):1–8.
59. Ayuso-Mateos JL. Depressive disorders in Europe: prevalence figures from the ODIN study. *Br J Psychiatry*. 2001 10 1;179(4):308–16. [PubMed: 11581110]
60. Crawford JR, Henry JD, Crombie C, Taylor EP. Normative data for the HADS from a large non-clinical sample. *Br J Clin Psychol Br Psychol Soc*. 2001 11;40(Pt 4):429–34.
61. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. *Trials*. 2012;13:132. [PubMed: 22867278]
62. Herrmann C International experiences with the Hospital Anxiety and Depression Scale—a review of validation data and clinical results. *J Psychosom Res*. 1997 1;42(1):17–41. [PubMed: 9055211]
63. Jutte JE, Needham DM, Pfoh ER, Bienvenu OJ. Psychometric evaluation of the Hospital Anxiety and Depression Scale 3 months after acute lung injury. *J Crit Care*. 2015 8;30(4):793–8. [PubMed: 25981443]
64. Kessler RC, Bromet EJ. The Epidemiology of Depression Across Cultures. *Annu Rev Public Health*. 2013 3 18;34(1):119–38. [PubMed: 23514317]
65. Huang M, Parker AM, Bienvenu OJ, Dinglas VD, Colantuoni E, Hopkins RO, et al. Psychiatric Symptoms in Acute Respiratory Distress Syndrome Survivors: A One-Year National Multi-Center Study. *Crit Care Med*.
66. Denollet J, Brutsaert DL. Reducing Emotional Distress Improves Prognosis in Coronary Heart Disease: 9-Year Mortality in a Clinical Trial of Rehabilitation. *Circulation*. 2001 10 23;104(17):2018–23. [PubMed: 11673339]
67. Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctôt KL. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. *Can J Psychiatry Rev Can Psychiatr*. 2010 2;55(2):91–9.
68. Parker AM, Bienvenu OJ. Posttraumatic Stress Disorder Symptoms Among Family Decision Makers and the Potential Relevance of Study Attrition*: *Crit Care Med*. 2015 6;43(6):1334–5. [PubMed: 25978160]
69. Long AC, Kross EK, Davydow DS, Curtis JR. Posttraumatic stress disorder among survivors of critical illness: creation of a conceptual model addressing identification, prevention, and management. *Intensive Care Med*. 2014 6;40(6):820–9. [PubMed: 24807082]
70. Quality of Life After Mechanized Ventilation in the Elderly Study Investigators. 2-month mortality and functional status of critically ill adult patients receiving prolonged mechanical ventilation. *Chest*. 2002 2;121(2):549–58. [PubMed: 11834671]
71. Broslawski GE, Elkins M, Albus M. Functional abilities of elderly survivors of intensive care. *J Am Osteopath Assoc*. 1995 12;95(12):712–7. [PubMed: 8557555]
72. Davydow DS, Russo JE, Ludman E, Ciechanowski P, Lin EHB, Von Korff M, et al. The Association of Comorbid Depression with Intensive Care Unit Admission in Patients with Diabetes: A Prospective Cohort Study. *Psychosomatics*. 2011 3;52(2):117–26. [PubMed: 21397103]
73. Quality of Life After Mechanized Ventilation in the Elderly Study Investigators. 2-month mortality and functional status of critically ill adult patients receiving prolonged mechanical ventilation. *Chest*. 2002 2;121(2):549–58. [PubMed: 11834671]
74. Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G. The Psychometric Properties of CollaboRATE: A Fast and Frugal Patient-Reported Measure of the Shared Decision-Making Process. *J Med Internet Res*. 2014;16(1):e2. [PubMed: 24389354]

Table 1.

Measurement of Depressive Symptoms Using Standardized Instruments

Study	Past psychiatric illness (%)	Instrument	Follow-up (mo.)	N at follow-up	Mean (SD) or median (IQR)	Cut-off score	Point prevalence (%)
Chelluri et al. (26)	-	CES-D	1 6 12	12; 12 12; 12 12; 12	10 (5.02) ^a ; 10 (5.99) ^b 8 (3.01) ^a ; 9 (5.4) ^b 6 (3.01) ^a ; 6 (1) ^b	-	-
Broslawski et al. (27)	-	GDS-SF	6	27	-	6	4
Eddleston et al. (28)	-	HADS-D	3	143	-	8; 11	9.8; 2.8
Kress et al. (49)	38 ^c ; 11 ^d	BDI-II	14 (5) ^c ; 12 (7) ^d	13 ^c ; 19 ^d	13.7 (9.7) ^c ; 17.2 (10.6) ^d	17	38 ^c ; 53 ^d
Jones et al. (29)	16	HADS-D	2	30	5.28 (4.42)	8; 11	20; 13.3
Scragg et al. (50)	-	HADS-D	13 (6)	80	-	8	30
Jackson et al. (30)	Excluded	GDS-SF	6	34	6.4 (4.3) ^e , 3 (3.4) ^f	6	24
Jones et al. (17)	Excluded	HADS-D	2 6	114 102	5.9 (4.4) 5.6 (3.9)	8; 11	39; 31 56; 36
Boyle et al. (31)	-	CES-D	1 6	55 51	19.22 (10.42) 13.79 (10.37)	-	-
Chelluri et al. (32) (73)	-	CES-D	2 12	129 154	14.1 (9.6) 12.16 (11.02)	16	35 32
Rattray et al. (33)	-	HADS-D	6 12	80 80	5.13 (3.56) 5.16 (4.28)	8; 11	26; 7 27; 11
Weinert et al. (34)	27 ^g	CES-D SCID	2 6 2	153 90 134	11, 8 11, 6-	- - -	27 33 33
Samuelson et al. (35)	-	HADS-D	2	226	1 (4)	11	7.5
Sukantarat et al. (36)	-	HADS-D	3 9	51 45	6.6 (4.5) 6.7 (4.8)	8; 11	35; 23.53 47; 31.11
McWilliams et al. (37)	-	HADS-D	1 w 2	38 38	7.2 (4.1) 4.4 (3.6)	8; 11	42; 13 10.5; 8
Cuthbertson et al. (18)	-	HADS-D	6 12	105 ^c , 115 ^d 93 ^c , 100 ^d	5.3 (4.3) ^c , 5.3 (4.0) ^d 4.8 (4.5) ^c , 4.8 (4.2) ^d	8; 11	27 ^c ; 12 ^c /28 ^d ; 13 ^d 27 ^c ; 13 ^c /28 ^d ; 11 ^d
Knowles et al. (19)	22.2 ^c 27.8 ^d	HADS-D	1 2	18 ^c ; 18 ^d 18 ^c ; 18 ^d	6.72 (4.64) ^c ; 8.89 (5.12) ^d 4.17 (2.98) ^c ; 8.29 (5.13) ^d	8	38.9 ^c , 55.6 ^d 16.7 ^c , 44.4 ^d
Myhren et al. (55)(39)	-	HADS-D	1 3 12	252 191 192	4.76 (4.15) 4.16 (3.92) 4.71 (4.23)	8; 11	23; 12 20; 8 27; 11

Study	Past psychiatric illness (%)	Instrument	Follow-up (mo.)	N at follow-up	Mean (SD) or median (IQR)	Cut-off score	Point prevalence (%)
Peek et al. (20)	-	HADS-D	6	50 ^c , 32 ^d	4.4 (0.6) ^c , 5.8 (0.7) ^d	8; 11	16; 8 ^c / 25; 12.5 ^d
Treggiari et al. (21)	-	HADS-D	1	52 ^c , 50 ^d	3.4 (3.7) ^c , 3.1 (3.7) ^d	8; 11	15; 8 ^c / 12; 4 ^d
Van der Schaaf et al. (38)	-	HADS-D	12	247	4.4 (4.25)	8; 11	22; 11
Jackson et al. (22)	-	BDI-II	3 12	47 ^c ; 32 ^d 35 ^c ; 25 ^d	13 (7-20) ^c ; 11 (7-17) ^d 12 (5-20) ^c ; 14 (6-20) ^d	>10	64 ^c , 58 ^d 59 ^c , 62 ^d
Rattray et al. (40)	-	HADS-D	2 6	63 50	6.98 (5.381) 6.22 (4.586)	8; 11	42.9; 25.4 32; 18
Strøm et al. (23)	8 ^c ; 23 ^d	BDI-II	24	13 ^c , 13 ^d	3 (1-7) ^c ; 3 (1-11) ^d	>10	8 ^c , 31 ^d
Garrouste-Orgeas et al. (14)	18.7 ^h 6.1 ⁱ 19.5 ^j	HADS-D	3	21 ^h 19 ⁱ 12 ^j	6.3 (6.9) ^h 3.7 (5.1) ⁱ 6.5 (4.7) ^j	8; 11	38.1; 28.6 ^h 15.8; 15.8 ⁱ 41.7; 25 ^j
McKinley et al. (42)	Excluded	DASS-21-D	1 w 2 6.5	156 156 156	8 (2-12) 4 (0-10) 4 (0.5-10)	14; 20	26.9; 13.7 16.6; 8.9 21.3; 9.4
Schandl et al. (43)	18 ^c ; 15 ^d	HADS-D	3 ^c 6 ^c 12 ^c 14 ^{c, d}	100 ^c 68 ^c 50 ^c 98 ^c ; 73 ^d	5.47 (4.15) ^c 5.02 (3.85) ^c 4.4 (3.12) ^c 4.78 (4.50) ^c ; 5.76 (4.54) ^d	8; 11	28; 13 ^c 25; 12 ^c 24; 2 ^c 21; 11 ^c / 33; 19 ^d
Wade et al. (44)	16 ^k	CES-D	3	100	-	19	46.30
Davydow et al. (45)	29 ^k	PHQ-9	3 12	131 120	-	10	31 17
Kowalczyk et al. (51)	-	HADS-D	34	186	7.82 (4.82)	8; 11	50; 27.4
Raveau et al. (46)	42 ^k	GDS-4 items	3	30	0 (0, 10)	1	43
Risnes et al. (54)	54	HADS-D	60	27	3.81 (3.3)	-	-
Jackson et al. (47)	34 ^k	BDI-II	3 12	407 347	10 (5, 17) 10 (4.6, 16.5)	14; 20	37; 20.4 33; 21
Paparrigopoulos et al. (52)	42	CES-D	21 (3)	48	13.3 (2)	16	31
Battle et al. (53)	10 ^k	HADS-D	3	63	6.8 (5.3)	8; 11	46; 25.4
Jones et al. (24) ^o	Excluded	HADS-D	3	14 ^l , 18 ^m , 19 ⁿ , 16 ^o	4.93 (4.2) ^l ; 2.74 (2.5) ^m ; 6.37 (4.6) ⁿ ; 4.81 (3.8) ^o	8; 11	29; 7 ^l / 5; 0 ^m / 37; 21 ⁿ / 19; 12 ^o
Parsons et al. (48)	24; 18 ^k	PHQ-9	12	120	-	10	18

Study	Past psychiatric illness (%)	Instrument	Follow-up (mo.)	N at follow-up	Mean (SD) or median (IQR)	Cut-off score	Point prevalence (%)
Walsh et al. (25)	-	HADS-D	3 6 12	98 ^c ; 87 ^d 86 ^c ; 80 ^d 81 ^c ; 77 ^d	6.45 (3.89) ^c ; 6.91 (4.27) ^d 7.17 (4.62) ^c ; 6.71 (4.81) ^d 6.87 (4.82) ^c ; 6.66 (4.14) ^d	8; 11	36.7; 15.3 ^c / 44.8; 22.9 ^d 50; 24.4 ^c / 43.7; 20 ^d 45.6; 24.6 ^c /40; 19.4 ^d

Abbreviations: N: Number; CES–D: Center for Epidemiological Studies Depression; GDS: Geriatric Depression Scale; HADS: Hospital Anxiety and Depression Scale; BDI: Beck Depression Inventory; SCID: Structured Clinical Interview for DSM-IV; DASS: Depression, Anxiety and Stress scales; PHQ: Patient Health Questionnaire; mo.: months

a: Age<75;

b: Age 75;

c: intervention;

d: control;

e: cognitively impaired based on neuropsychological battery;

f: cognitively non-impaired;

g: depressed in last month (per proxy);

h: pre-diary;

i: dairy;

j: post diary;

k: History of depression;

l: Control supplement, no PEPSE (outpatient physiotherapy class),

m: Control supplement, PEPSE,

n: EAA (essential amino acid) supplement, no PEPSE,

o: EAA supplement, PEPSE

Table 2.

Meta-analysis of Depression Prevalence in ICU Survivors

	2,3 months	6 months	12,14 months
Using HADS-D 8			
<i>No. studies</i>	12 ^a	7 ^b	6 ^c
<i>No. patients</i>	1,078	760	1,041
<i>Prevalence (95% CI)</i>	29% (22–36)	34% (24–43)	29% (23–34)
<i>I²</i>	84%	88%	76%
Using multiple instruments compatible with HADS-D 8 (Including HADS-D 8, BDI-II 14 & 16, CES-D 16, GDS-SF 6)			
<i>No. studies</i>	15 ^d	10 ^e	8 ^f
<i>No. patients</i>	1,767	911	1,542
<i>Prevalence (95% CI)</i>	30% (24–35)	29% (20–39)	30% (25–34)
<i>I²</i>	84%	91%	72%
Using HADS-D 11			
<i>No. studies</i>	12 ^a	7 ^b	6 ^c
<i>No. patients</i>	1,078	760	1,041
<i>Prevalence (95% CI)</i>	17% (12–21)	17% (10–23)	13% (10–16)
<i>I²</i>	77%	83%	52%
Using multiple instruments compatible with HADS-D 11 (Including HADS-D 11, PHQ-9 10, DASS 21-D 14, CES-D 19)			
<i>No. studies</i>	16 ^g	8 ^h	9 ⁱ
<i>No. patients</i>	1,812	916	1,628
<i>Prevalence (95% CI)</i>	20% (15–24)	17% (12–23)	15% (12–18)
<i>I²</i>	86%	82%	66%

ICU: Intensive Care Unit; No: Number; CI: Confidence Interval; HADS-D: Hospital Anxiety and Depression Scale-Depression Subscale; CES-D: Center for Epidemiological Studies Depression; GDS: Geriatric Depression Subscale; BDI: Beck Depression Inventory; PHQ-9: Patient Health Questionnaire; DASS: Depression, Anxiety and Stress Scale

^a: Relevant references: 17,18,24,25,36,37,39–41,43,50,53

^b: Relevant references: 17,18,20,25,33,40,43

^c: Relevant references: 18,25,33,38,39,43

^d: Relevant references: 17,18,24,25,34,36,37,39–41,43,47,50,53,70

^e: Relevant references: 17,18,20,25,30,33,34,40,43,71

^f: Relevant references: 18,25,32,33,38,39,43,47

^g: Relevant references: 17,18,24,25,36,37,39–45,47,50,53

^h: Relevant references: 17,18,20,25,33,40,42,43

ⁱ: Relevant references: 18,25,33,38,39,43,47,48,72

Table 3.

Association of Depressive Symptoms With Pre-ICU, ICU, and Post-ICU Factors

Risk factors	Total	No Association		Positive Association (greater depressive symptoms)	
	N	N	%	N	%
Pre-ICU factors					
Older age	11	9	82%	2	18%
Sex	8	8	100%	0	0%
Ethnicity	2	2	100%	0	0%
Low income and socioeconomic status	3	0	0%	3	100%
Low employment status	2	0	0%	2	100%
Low educational status	4	3	75%	1	25%
Marital status	3	3	100%	0	0%
Pre-ICU psychological morbidity	5	1	20%	4	80%
History of traumatic event	2	1	50%	1	50%
Chronic physical health morbidities ^a	4	4	100%	0	0%
ICU factors					
Benzodiazepines/ days of sedation	3	3	100%	0	0%
Sedation minimization ^b	4	4	100%	0	0%
Duration of MV	4	3	75%	1	25%
Antipsychotics in ICU	2	2	100%	0	0%
Opioids in ICU	3	3	100%	0	0%
Delirium	3	2 ^c	67%	1	33%
Severity of illness ^d	6	6	100%	0	0%
TISS score	2	2	100%	0	0%
ICU LOS, Hospital LOS	5	5	100%	0	0%
Admission diagnosis	6	5	83%	1	17%
ICU experience ^e	2	2	100%	0	0%
Psychological symptoms in ICU/Hospital ^f	4	0	0%	4	100%
Post-ICU factors					
Time since hospital d/c ^g	8	6	75%	2	25%
Having Delusional memories	2	0	0%	2	100%
No factual memories from ICU stay	5	2	40%	3	60%
Quality of life	2	0	0%	2	100%
Psychiatric problems post-ICU ^h	5	0	0%	5	100%

Abbreviations: ICU: intensive care unit; N: number; SBTs: Spontaneous breathing trials; d/c: discharge; LOS: length of stay; TISS: Therapeutic intervention scoring; MV: mechanical ventilation;

^a: Depression, Psychological history in general;

^b: Two daily sedative interruption protocols, one light sedation and one no sedation protocol;

^c: One study was unable to show association at first time point (3 months), but found positive association at 12 months.

d. APACHE II/ SAPS II;

e. Awareness of surroundings; Satisfaction with care; Frightening experiences;

f. ICU mood, acute stress, stressful experiences, depressive symptoms;

g. Change in depressive symptoms longitudinally comparing 2 time points **after** hospital discharge, only 2 showed decrease in depressive symptoms over time;

h. anxiety and PTSD

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4.

Association of Post-ICU Interventions with Depressive Symptoms

Post-ICU Interventions	Total		No Association		Negative Association (less depressive symptoms)	
	N	%	N	%	N	%
Rehabilitation during post-ICU hospitalization	1	100%	1	100%	0	0%
Physical Rehabilitation after discharge ^a	3	0%	1	0%	2	67%
Antidepressant +self-help manual vs antidepressant alone ^b	1	0%	0	0%	1	100%
ICU Diary	2	100%	2	100%	0	0%
Nurse-led ICU follow-up clinic	1	100%	1	100%	0	0%

Abbreviations: ICU: intensive care unit; N: number

^a: In one RCT, physical rehab plus essential amino acid supplement was effective;

^b: Self-help manual (rehabilitation package) alone reduced the rate of depressive symptoms but did not reach statistical significance (P=0.066)